Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida

References

• Aaron, S., J. S. McMahon, D. Milano, L. Torres, M. Clatts, S. Tortu, D. Mildvan, and M. Simm. 2008. Intranasal transmission of Hepatitis C Virus: Virological and clinical evidence. Clinical Infectious Diseases 47 (7):931–34. doi:10.1086/591699.
   PubMed Web of Science ®Google Scholar
• Alabama State Board of Health. 2019. Controlled substances list. Accessed February 7, 2020. https://www.alabamapublichealth.gov/publications/assets/controlledsubstanceslist.pdf.
   Google Scholar
• Applewhite, D. S., K. K. Regan, S. Mackin, C. Schmidt, and S. E. Wakeman. 2020. Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. International Journal of Drug Policy 79:102752. doi:10.1016/j.drugpo.2020.102752.
   PubMed Web of Science ®Google Scholar
• Baird, C. R. W., P. Fox, and L. A. Colvin. 2013. Gabapentin abuse in order to potentiate the effect of methadone: A survey among substance misusers. European Addiction Research 20 (3):115–18. doi:10.1159/000355268.
   PubMed Web of Science ®Google Scholar
• Bastiaens, L., J. Galus, and C. Mazur. 2016. Abuse of gabapentin is associated with opioid addiction. Psychiatric Quarterly 87 (4):763–67. doi:10.1007/s11126-016-9421-7.
   PubMed Web of Science ®Google Scholar
• Berlin, R. K., P. M. Butler, and M. D. Perloff. 2005. Gabapentin therapy in psychotic disorders: A systematic review. The Primary Care Companion for CNS Disorders 17 (5). doi:10.4088/PCC.15r01821.
   Google Scholar
• Brockbrader, H. N., D. Wesche, R. Miller, S. Chapel, N. Janiczek, and P. Burger. 2010. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics 49 (10):661–69. doi:10.2165/11536200-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., S. P. Kurtz, T. J. Cicero, and J. R. Havens. 2019a. An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)users. Drug and Alcohol Dependence 204:107554. doi:10.1016/j.drugalcdep.2019.107554.
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., S. P. Kurtz, R. C. Dart, and Z. R. Margolin. 2017. Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: Diversion rates and qualitative research findings. Pharmacoepidemiology and Drug Safety 26 (9):1083–86. doi:10.1002/pds.4230.
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., S. P. Kurtz, M. S. Ellis, and T. J. Cicero. 2019b. Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. Journal of Substance Abuse Treatment 105:1–4. doi:10.1016/j.jsat.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Chatterjee, A., D. Lopez, S. Ramkellawan, R. Brown, K. Smith, J. M. Gaeta, and T. P. Baggett. 2019. “That’s what we call the cocktail”: Non-opioid medication and supplement misuse among opioid users. Substance Abuse 1–8. doi:10.1080/08897077.2019.1671943.
   PubMed Web of Science ®Google Scholar
• Colorafi, K. J., and B. Evans. 2016. Qualitative descriptive methods in health science research. HERD: Health Environments Research & Design Journal 9 (4):16–25. doi:10.1177/1937586715614171.
   Web of Science ®Google Scholar
• Embers, D., D. A. Ravishankar, and S. Roopa. 2019. Gabapentin and buprenorphine nasal insufflation in a patient on buprenorphine for opioid use disorder. American Journal of Hospital Medicine 3 (2):2019.005. doi:10.24150/ajhm/2019.005.
   Google Scholar
• Evoy, K. E., M. D. Morrison, and S. R. Saklad. 2017. Abuse and misuse of pregabalin and gabapentin. Drugs 77 (4):403–26. doi:10.1007/s40265-017-0700-x.
   PubMed Web of Science ®Google Scholar
• Global Appraisal of Individual Needs. 2016. Global appraisal of individual needs – individual (GAIN-I), version [GVER]: 5.7.6. Bloomington, IL: Chestnut Health Systems.
   Google Scholar
• Gomes, T., D. N. Juurlink, T. Antoniou, M. M. Mamdani, J. M. Paterson, and W. van den Brink. 2017. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Medicine 14 (10):e1002396. doi:10.1371/journal.pmed.1002396.
   PubMed Web of Science ®Google Scholar
• Goodman, C. W., and A. S. Brett. 2017. Gabapentin and pregabalin for pain - Is increased prescribing a cause for concern? New England Journal of Medicine 377 (5):411–14. doi:10.1056/NEJMp1704633.
   PubMed Web of Science ®Google Scholar
• Inciardi, J. A., H. L. Surratt, S. P. Kurtz, and J. J. Burke. 2006. The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Substance Use and Misuse 41 (2):255–64. doi:10.1080/10826080500391829.
   PubMed Web of Science ®Google Scholar
• King, L. 2020. State-imposed restrictions on gabapentin. Accessed February 7, 2020. https://www.medval.com/2020/01/08/state-imposed-restrictions-on-gabapentin/.
   Google Scholar
• MacDonald, M., N. Crofts, and J. Kaldor. 1996. Transmission of Hepatitis C virus: Rates, routes, and cofactors. Epidemiologic Reviews 18 (2):137–48. doi:10.1093/oxfordjournals.epirev.a017921.
   PubMed Web of Science ®Google Scholar
• Mincher, T. 2018. Gabapentin is a schedule V controlled substance as of July 1, 2018. Tennessee Veterinary Medical Association. Accessed January 29, 2020. http://tvmanet.com/2018/06/29/gabapentin-is-a-schedule-v-controlled-substance-as-of-july-1-2018/.
   Google Scholar
• North Dakota State Board of Pharmacy. 2019. Gabapentin added as a schedule V substance in the North Dakota controlled substanced act. Accessed February 7, 2020. https://nabp.pharmacy/wp-content/uploads/2016/06/North-Dakota-Newsletter-June-2019.pdf.
   Google Scholar
• Peckham, A. M., M. Ananickal, and D. Sclar. 2018. Gabapentin use, abuse, and the US opioid epidemic: The case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Management and Healthcare Policy 11:109–16. doi:10.2147/RMHP.S168504.
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., K. A. Fairman, and D. Sclar. 2018. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: A retrospective cohort analysis of a commercially Insured US population. Drug Safety 41 (2):213–28. doi:10.1007/s40264-017-0595-1.
   PubMed Web of Science ®Google Scholar
• Quintiles IMS Institute. 2017. Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Accessed December 4, 2019. https://structurecms-staging-psyclone.netdna-ssl.com/client_assets/dwonk/media/attachments/590c/6aa0/6970/2d2d/4182/0000/590c6aa069702d2d41820000.pdf?1493985952.
   Google Scholar
• Reeves, R. R., and M. E. Ladner. 2014. Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine. The American Journal of Psychiatry 171 (6):691. doi:10.1176/appi.ajp.2014.13111526.
   PubMed Web of Science ®Google Scholar
• Saldaña, J. 2013. The coding manual for qualitative researchers. Los Angeles, CA: Sage.
   Google Scholar
• Smith, R. V., E. M. Boland, A. M. Young, M. R. Lofall, A. Quiroz, M. Staton, and J. R. Havens. 2018. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychology of Addictive Behaviors 32 (1):115–21. doi:10.1037/adb0000337.
   PubMed Web of Science ®Google Scholar
• Smith, R. V., M. R. Lofwall, and J. R. Havens. 2015. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. American Journal of Psychiatry 172 (5):487–88. doi:10.1176/appi.ajp.2014.14101272.
   PubMed Web of Science ®Google Scholar
• Stein, M. D., S. R. Kenney, B. J. Anderson, M. T. Conti, and G. L. Bailey. 2020. Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification. Journal of Substance Abuse Treatment 110:37–41. doi:10.1016/j.jsat.2019.12.007.
   PubMed Web of Science ®Google Scholar
• Wallach, J. D., and J. S. Ross. 2018. Gabapentin approvals, off-label Use, and lessons for postmarketing evaluation efforts. JAMA 319 (8):776–78. doi:10.1001/jama.2017.21897.
   PubMed Web of Science ®Google Scholar
• Wilens, T., C. Zulauf, D. Ryland, N. Carrellas, and I. Catalina-Wellington. 2015. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. The American Journal on Addictions 24 (2):173–77. doi:10.1111/ajad.12159.
   PubMed Web of Science ®Google Scholar